Su Di-Ya, Zou Mu-Yan, Wang Shi-Wei, Dong Lei, Wu Jia-Xu, Hu Xi-Yue, Wang Jie-Qing
Plastic & Aesthetic Surgery Center, Dalian University Affiliated Xinhua Hospital, Dalian, Liaoning, China.
Medical Department, Imeik Technology Development Co. Ltd, Beijing, China.
J Cosmet Dermatol. 2025 Feb;24(2):e16718. doi: 10.1111/jocd.16718. Epub 2025 Jan 14.
Tear trough deformities are indicative of aging, progressively manifesting as pronounced infraorbital hollows. Although hyaluronic acid (HA) dermal fillers are favored for their safety and efficacy, quantifiable evidence of their effect of action still remains insufficient.
To investigate the efficacy of non-cross-linked HA compound in tear trough enhancement.
Twenty-one subjects with moderate to severe infraorbital hollows underwent a single treatment including subcutaneous to supraperiosteal injections of a non-cross-linked HA compound. The effectiveness was assessed through Allergan Infraorbital Hollows Scale (AIHS), satisfaction rates, the Global Aesthetic Improvement Scale (GAIS), and quantitative analyses via Canfield VECTRA 3D imaging and MRI measurements during the 6-month follow-up.
A total of 0.67 ± 0.31 and 0.77 ± 0.42 mL of the non-cross-linked HA compound were injected into the left and right suborbital regions, respectively. Substantial improvements in AIHS were observed in 85.71% and 80.95% of subjects at 6 months posttreatment, as assessed by blinded evaluators and treating investigators, respectively. 3D imaging showed volume increases of 0.87 ± 0.32 (left) and 0.99 ± 0.45 mL (right). MRI analysis provided closely aligned results to the 3D analysis. The GAIS and satisfaction rate were 85.71%, 90.48% for treating investigators and were 90.48% and 95.24% for subjects 6 months posttreatment.
The non-cross-linked HA filler demonstrated a safe and efficacious profile for the correction of infraorbital hollows with significant patient satisfaction and sustained outcomes up to 6 months posttreatment. These results support their clinical value in periorbital rejuvenation and reduction of infraorbital hollowing.
泪沟畸形是衰老的表现，逐渐表现为明显的眶下凹陷。尽管透明质酸（HA）真皮填充剂因其安全性和有效性而受到青睐，但其作用效果的可量化证据仍然不足。
研究非交联HA复合物改善泪沟的疗效。
21例中重度眶下凹陷患者接受单次治疗，包括皮下至骨膜上注射非交联HA复合物。在6个月的随访期间，通过艾尔建眶下凹陷量表（AIHS）、满意率、全球美容改善量表（GAIS）以及使用Canfield VECTRA 3D成像和MRI测量进行定量分析来评估疗效。
分别向左右眶下区域注射了总量为0.67±0.31和0.77±0.42 mL的非交联HA复合物。治疗6个月后，经盲法评估者和治疗研究者评估，分别有85.71%和80.95%的受试者的AIHS有显著改善。3D成像显示左侧体积增加0.87±0.32 mL，右侧增加0.99±0.45 mL。MRI分析结果与3D分析结果密切一致。治疗研究者的GAIS和满意率在治疗6个月后分别为85.71%、90.48%，受试者的GAIS和满意率分别为90.48%和95.24%。
非交联HA填充剂在矫正眶下凹陷方面显示出安全有效的特点，患者满意度高，治疗后6个月效果持续。这些结果支持了其在眶周年轻化和减少眶下凹陷方面的临床价值。
